Objective: The vaginal microbiota helps protect the female genital tract from disease. We sought to describe the composition of the vaginal microbiota in premenopausal, perimenopausal, and postmenopausal women and to explore the association between the microbiota and vulvovaginal atrophy (VVA).
affect the vaginal epithelium, lamina propria, and vaginal microbiota. [11] [12] [13] [14] New interventions are needed to reduce vulvovaginal symptoms caused by VVA in postmenopausal women. 15 One approach to VVA that has not been well explored is harnessing the protective features of the vaginal microbiome. 16, 17 The vaginal microbiota plays an important role in preventing colonization by pathogenic organisms, including sexually transmitted and urinary tract infectious agents, and broadly acts to maintain a woman's gynecologic and reproductive health. [18] [19] [20] The predominant connection between the vaginal microbiome and menopause occurs through the influential action of estrogen. Estrogen contributes to vaginal epithelium maturation through the deposition of glycogen in the vaginal epithelium. 3 Glycogen is metabolized by indigenous bacterial communities to produce organic acids (primarily lactate), which is thought to protect the genital tract. 21 Prior studies of vaginal bacteria have largely been conducted using bacteriological culture techniques; however, a majority of microbial species (>90%) resist cultivation in the laboratory. 22, 23 A complete characterization of the vaginal microbiota requires molecular approaches. 24 To date, molecular studies (cultivation-independent censuses) of the vaginal microbiota have focused on reproductive-age women, mainly aged 18 to 45 years. [25] [26] [27] [28] These studies have found a multitude of bacteria that could not be identified by traditional culture-based methods. 29, 30 Molecular studies by Srinivasan et al and Gajer et al 31 showed that the diversity, composition, and relative abundance of microbial species in the vagina vary dramatically, and Ravel et al 28 demonstrated that reproductive-age women can be grouped into five consistent categories referred to as community state types (CSTs). As community state types (CSTs). These five CSTs are often dominated by Lactobacillus crispatus (CST I), Lactobacillus gasseri (CST II), Lactobacillus iners (CST III), or Lactobacillus jensenii (CST V), whereas the fifth CST (CST IV) has lower proportions of Lactobacillus spp. and higher proportions of anaerobic organisms, including Mobiluncus spp. and Atopobium vaginae. CST IV was recently divided into two substates, termed CST IV-A and CST IV-B, by Gajer et al. 32 CST IV-A is characterized by various species of anaerobic bacteria belonging to the genera Anaerococcus, Peptoniphilus, Prevotella, and Streptococcus, whereas CST IV-B has higher proportions of the genera Atopobium and Megasphaera, among others. Species-specific differences in the vaginal microbiota have been shown to be important, such as in a recent study by Srinivasan et al, 26 where various bacterial species were associated with each of the four Amsel clinical signs of bacterial vaginosis (BV), suggesting links between specific vaginal bacteria and clinical signs.
In this study, we seek to determine whether the composition of the vaginal microbiota differs between premenopausal, perimenopausal, and postmenopausal women, using cultureindependent techniques, and to explore the association between the vaginal microbiota and signs of VVA.
METHODS

Study population and specimen collection
Women included in this study were enrolled in a prospective cohort study assessing human papillomavirus in perimenopause (HIP Study), which has been previously described. [33] [34] [35] [36] Briefly, 885 women (aged 35-60 y) attending one of four outpatient gynecology clinics in Baltimore, MD, for routine examination were enrolled. Women were eligible for enrollment if they were not currently pregnant, had an intact uterus, and had no history of organ transplantation or human immunodeficiency virus infection. Medication use was also recorded. One woman in our study sample reported use of prednisone, and another reported use of tamoxifen.
Menopausal stage was determined using the Stages of Reproductive Aging Workshop (STRAW) staging system, 37 which is based on the day of the last menstrual cycle and selfreported cycle length variability in the past 2 months. Women were classified as premenopausal if they had a menstrual period in the past 2 months and reported no menstrual cycle variability. Currently menstruating women who reported menstrual cycle length variability were considered perimenopausal, and women without a menstrual cycle in the past 2 months were considered postmenopausal. The vaginal maturation index, which assesses parabasal, intermediate, and superficial vaginal epithelial cell types, was not determined because it is not used in clinical practice 1 and was not used in the context of the HIP Study.
An interviewer-administered questionnaire collected detailed information on demographics, gynecologic and menstrual history, medication use, history of exogenous hormone use, current and past sexual behaviors, sexual functioning, general medical history, and tobacco and alcohol use. Participants underwent standardized clinical assessment and pelvic examination with clinician inspection for vaginal atrophy, including signs of vaginal pallor, dryness, rugosity, blanching of tissue, friability, and petechiae. The clinician performed a speculum-assisted examination and collected a cervical swab for human papillomavirus testing (Digene HPV sampler kit) and a midvaginal swab for microbiota analysis (Elution Swab system with 1 mL of Amies transport media; Copan Diagnostics Inc, Murrieta, CA). Samples were frozen at À80 8C immediately after collection until processed.
For the purposes of this substudy on the composition of vaginal bacterial communities, we randomly selected 90 women-evenly split across premenopause, perimenopause, and postmenopause-for a cross-sectional analysis at their baseline visit. Additional inclusion criteria for these women were as follows: human papillomavirus-negative, no selfreported history of sexually transmitted infection in the past 6 months, no diagnosis of BV or other sexually transmitted infections at the current visit, and no exogenous hormone use. The final data set included 87 women with complete data on bacterial composition and VVA: 30 women in premenopause (STRAW À3), 29 womeninperimenopause (STRAW À1 and BROTMAN ET AL STRAW À2), and 28 women in postmenopause (STRAW þ1 and STRAW þ2).
All study procedures were approved by the Johns Hopkins Bloomberg School of Public Health and the University of Maryland School of Medicine institutional review boards.
Composition of vaginal bacterial communities DNA extraction, 16S ribosomal RNA gene amplification, and pyrosequencing DNA extraction from vaginal swabs, polymerase chain reaction amplification of the V1-V2 hypervariable regions of 16S ribosomal RNA genes using primers barcoded 27F and 338R, 38 and pyrosequencing were performed as previously described. 28 Microbiome analysis was blinded to menopause status and age.
Sequence analysis
The split-library.pl script part of the QIIME software package 28 was used for quality control of sequence reads using the following criteria: (1) no base ambiguity; (2) minimal and maximal read lengths of 220 and 400 bp, respectively; (3) average read quality of q25 for a sliding window of 50 bp (if the read quality dropped below q25, it was trimmed at the first base pair of the window and reassessed for length criteria); (4) perfect match to a barcode sequence; and (5) presence of the 338R 16S primer sequence used for amplification. Sequences were binned based on sample-specific barcode sequences and trimmed by removal of the barcode and primer sequences (forward, if present, and reverse). High-quality sequence reads were first dereplicated with 99% similarity using the UCLUST software package, 39 and detection of potential chimeric sequences was performed using the UCHIME component of UCLUST. 40 Chimeric sequences were removed before taxonomic assignments.
Genus-level taxonomic assignments were performed with the RDP Classifier, 41 and further species-level assignments of Lactobacillus spp. were performed with 126 HMM Lactobacillus species models using the software speciateIT (speciateIT.sourceforge. net). 28 For each sample, vectors of phylotype proportions were clustered into CSTs as previously described by Gajer et al. 32 
Statistical analysis
We sought to describe the differences in vaginal bacterial community composition between premenopausal, perimenopausal, and postmenopausal women and to evaluate clinical associations with the vagina's bacterial composition and abundance. Unadjusted associations were assessed using Fisher's exact test. Bayesian multinomial logistic regression was used to model the microbiota because CST (the outcome) consisted of six categories and the data were too sparse for large-sample frequentist inference. 42, 43 For all analyses, CST I (dominated by L. crispatus) was treated as reference because it was the most common CST. Models were adjusted for the following confounders: sexual activity in the past 6 months, race/ethnicity, marital status, and lifetime number of sex partners. Estimation was carried out using Markov chain Monte Carlo sampling. Convergence of the Markov chain was assessed using Geweke, Heidelberger-Welch, and Raftery diagnostics. [44] [45] [46] To ensure model convergence, we combined some CSTs such that no categories had zero women. CST IV-A and CST IV-B were combined to overcome data sparseness and because they were both low-Lactobacillus states with a large degree of overlap on the diversity of other anaerobes. 32 CST II and CST V were also combined to overcome data sparseness (there were relatively few women in each; L. gasseri/L. jensenii-dominated) and because both of these Lactobacillus species were considered in epidemiologic studies to be protective based on BV, metabolomics, and pH outcomes. 28, 47 Among women who were classified as non-Lactobacillusdominated CST IV-A and CST IV-B, sensitivity analysis was performed by evaluating the abundance of 205 individual bacteria in their association with menopause status and clinical outcomes using redundancy analysis, controlling for confounding factors. Redundancy analysis is a dimension reduction approach based on principal components. 48 Model inference is performed using multivariate analysis of variance and is tested using permutation test. Analyses were performed in R version 2.15.1 using the Zelig, MCMCpack, CODA, and vegan packages. [48] [49] [50] [51] Statistical significance was defined as P < 0.05 or Bayesian credible intervals (CrIs) for odds ratios excluding 1.
RESULTS
Using methods we have described previously, 32 we classified the bacterial communities of the 87 women into one of six CSTs based on differences in species composition and their relative abundances. The 25 most abundant bacteria (of 205 observed) are displayed in Fig. 1 . Lactobacillus spp. were the dominant members of the vaginal microbiota in each stage of the menopausal transition (83% in premenopause, 83% in perimenopause, and 54% in postmenopause).
Demographic and clinical factors at baseline are presented in Table 1 . Among postmenopausal women, 29% were classified as CST IV-A, 25% were classified as CST I (L. crispatus-dominated), and 18% were classified as CST III (L. iners-dominated). Forty-six percent of premenopausal women were dominated by L. crispatus (CST I), whereas 38% of perimenopausal women were dominated by L. iners (CST III). On clinical examination, 19 women (14 of which were postmenopausal) were found to have mild or moderate vaginal atrophy. Distribution of CSTs, signs of vaginal atrophy, and age were the only significant differences observed between premenopausal, perimenopausal, and postmenopausal women. Table 2 displays the distribution of women by CST and signs of VVA. Women classified as CST IV-A were noted by the clinicians to have the most severe signs of VVA.
To model the association between menopause stage and CST (Fig. 2, Table 3 Although there were only two cases of atrophic vaginitis that required prescription treatment (too few for regression modeling), it is notable that both were assigned to CST IV-A, a state with relatively low Lactobacillus abundance. Both cases were postmenopausal women (Tables 1, 4 
FIG. 2.
Odds ratios for community state type (CST) by menopausal stage, adjusted for sexual activity in the past 6 months, race/ethnicity, marital status, and lifetime number of sex partners.
BROTMAN ET AL
Because CST IV-A and CST IV-B had higher microbial diversity and were associated with signs of VVA, we sought to determine if specific bacteria contributed to the association in a higher-resolution analysis restricted to these two state types. Among all women (all menopausal stages) assigned to CST IV-A and CST IV-B, there were no statistically significant associations between clinical findings (menopause, VVA, and vaginal dryness) and any individual bacteria comprising these two CSTs, with adjustment for confounding variables.
DISCUSSION
There is mounting evidence that the human microbiome in later stages of life is very different from that in younger adults. 52, 53 Little is known about the composition of the vaginal microbiota across the stages of the menopausal transition, its interactions with estrogen, or its associations with gynecologic complaints and sexual functioning in menopause. In this study, we found significant associations between vaginal bacterial composition and both menopause stage and signs of vaginal atrophy. We identified a novel community assemblage (CST IV-A) that was highly associated with signs of VVA and predominantly found among postmenopausal women. CST IV-A is a low-Lactobacillus state typified by a higher abundance of genera, including Anaerococcus, Peptoniphilus, and Prevotella, which could be playing a putative role in the clinical presentation of VVA. The transition to CST IV-A may begin in perimenopausal women who tend to be dominated by either L. iners or CST IV-A. L. iners is unusual among lactobacilli in that some strains may have pathogenic effects, and the current thought is that some strains may not be as protective and are less efficient at maintaining a stable vaginal microenvironment. 32 , 54 Rampersaud et al 55 hypothesized that inerolysin, a cholesterol-dependent cytolysin produced by L. iners, plays a role in disease pathogenesis and affects the vaginal microbiota. Future work should follow women as they transition through menopause and should document individual-level changes in the vaginal microbiota and their associations with clinical outcomes. Such work could lead to interventions that maintain a woman's premenopausal vaginal microbiota through menopause and could evaluate if the vaginal microbiota protects the female reproductive tract in menopause. Interventions might include prebiotics and probiotics, alone or in conjunction with antibiotics, 17, 56 and changes in behaviors that are thought to negatively affect the vaginal microbiota (eg, smoking 57, 58 or lubricant use 14, 59 ). Estrogen therapy is known to be effective for the treatment of VVA; concomitantly, hormonal replacement increases the abundance of vaginal Lactobacillus spp. [60] [61] [62] However, the independent contribution of the increase in Lactobacillus to the improvement of VVA symptoms is not known. A study by Petricevic et al 17 found that orally administered probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 improved the Nugent Gram stain scores of vaginal smears, suggestive of an increased abundance of Lactobacillus spp., but they did not report on changes in atrophic symptoms. Gram stain scoring is based on morphologic assessment; therefore, bacterial assignments may be inaccurate. 20 Future work could consider vaginal specimen assessments using molecular techniques.
The results of our study based on 16S gene analysis are consistent with prior work conducted using bacteriological cultivation techniques. In 1997, Hillier and Lau 63 reported on the vaginal bacteria of 73 postmenopausal women who had not received estrogen therapy. Using biochemical assays, Gram's stain and cultivation to characterize bacteria, they found that 49% of women harbored Lactobacillus spp. and that, among those who did, concentrations were 10-fold to 100-fold less than those observed in premenopausal women. Prevotella bivia (33% of women), Gardnerella vaginalis (27% of women), Ureaplasma urealyticum (13% of women), and Candida albicans (1% of women) were also reported. In a 2003 study that characterized bacteria in the vaginal introitus using cultivation techniques, Pabich et al 64 found that Lactobacillus spp. were present in most postmenopausal women (60%), although they were more commonly found in women taking hormone therapy. In 2004, Burton et al 65 reported A. vaginae as a common member of the vaginal microbiota of postmenopausal women. Our study of 87 women expands the 2011 work of Hummelen et al, 16 who used 16S ribosomal RNA gene sequencing to characterize the vaginal microbiota of 32 postmenopausal women and found an inverse correlation between Lactobacillus and dryness, as well as increased bacterial diversity in women experiencing moderate to severe vaginal dryness. Among participants not reporting symptoms, L. iners and L. crispatus were generally the most abundant. 
VAGINAL MICROBIOTA AND MENOPAUSE
Our study overcame some of the limitations of prior studies by recruiting women in various phases of menopause and by using molecular techniques that can characterize the complete bacterial composition of the microbiome. Of interest for future research is the association between the vaginal microbiota and aerobic vaginitis (AV), as described by Donders et al. 66 Donders et al designated AV as a less severe form of desquamative inflammatory vaginitis. AV may be common in postmenopausal women and is distinct from BV. Its diagnosis is based on microscopy (bacterial composition), host response (elevated levels of the proinflammatory cytokines interleukin-6 and interleukin-1b), yellow discharge, and foul (but not fishy) odor. Based on our preliminary bacterial findings, it is possible that CST IV-A is common in AV.
Strengths of this study include its large sample size (the largest sample size to date) of premenopausal, perimenopausal, and postmenopausal women evaluating the vaginal microbiota in all phases of the menopausal transition, using cultivation-independent methods. In addition, the study used standardized clinical examinations, and VVA signs could be individually evaluated.
The study design has several limitations. The HIP Study was not designed to recruit women with atrophic vaginitis; therefore, there were only two cases that required treatment in the substudy. However, we presented data on 19 women described by clinicians as having mild to moderate vaginal atrophy on pelvic examination. The overall sample size (N ¼ 87) is still relatively limited, resulting in wide CrIs. These wide intervals underscore the uncertainty of the results and the need for larger studies. However, the findings will fuel hypothesis-driven work on the role of CST IV-A microbiota in VVA. In addition, this analysis was a cross-sectional study of women at different stages of menopause. Future research will characterize the dynamics of the vaginal microbiota in women as they are prospectively followed during the stages of menopause. G. vaginalis, a bacterium known to be a key member in the vagina, could be underrepresented in this study because of the use of the primer sets 27F and 338R; however, there are known biases with any primer set. There may be other unknown confounding factors that need to be controlled for in the analysis. Self-reported symptoms of vaginal atrophy were not collected at the baseline visit; however, vaginal symptoms, sexual activity, and sexual functioning were queried at follow-up visits and hence were not included in this analysis. Lastly, there may be misclassification of STRAW staging because of errors in self-reports of menstrual cycle. However, results were consistent when evaluated by age categories (data not shown).
CONCLUSIONS
Our data provide evidence that there are differences in bacterial communities between premenopause, perimenopause, and postmenopause, and we hypothesize that these anaerobes may play a role in the signs and symptoms of VVA. Probiotic pessaries may not necessarily be the answer because shifting the vaginal microbiome and host responses is probably a complex undertaking. We hypothesize that the use of generic lactobacilli-containing probiotics in women where the Lactobacillus species in the product are not indigenous may upset homeostatic mechanisms. Personalized treatments should rationally select probiotics based on a better appreciation of species-specific 28 and temporal differences 32 in vaginal ecology.
This work and future work are expected to lead to the development of studies designed to manage, modulate, and restore vaginal microbiota homeostasis in an effort to improve the treatment and prevention of VVA.
